Sun.Feb 25, 2024

article thumbnail

Rare Disease Day 2024 – The importance of shining a light on rare diseases

pharmaphorum

Rare Disease Day 2024 is an important opportunity to raise awareness about rare diseases and the need for research, diagnosis, and treatment options like orphan drugs. Learn the significance of shining a light on rare diseases.

Drugs 115
article thumbnail

Post?COVID-19 Kidney Outcomes

JAMA Internal Medicine

This cohort study assesses long-term kidney outcomes among hospitalized patients with COVID-19−associated acute kidney injury.

84
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Interchangeable high-concentration Humira approved in US

pharmaphorum

TevaU and Alvotech claim first US approval for first biosimilar of AbbVie’s high-concentration Humira, which accounts for 88% of brand prescriptions

article thumbnail

CymaBay's seladelpar has the potential to raise the bar in treatment for PBC

Outsourcing Pharma

Results from a phase 3 trial looking at treatment for primary biliary cholangitis (PBC) are 'genuinely exciting' and supports the potential for seladelpar to raise the bar in treatment of the disease.

Trials 84
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Which pharmaceutical companies have the most drug patents in Serbia?

Drug Patent Watch

This chart shows the pharmaceutical companies with the most patents in Serbia. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is… The post Which pharmaceutical companies have the most drug patents in Serbia? appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 81
article thumbnail

The Role of Real-World Evidence (RWE) in Drug Development: ProRelix Research Insights

ProRelix Research

The role of Real-World Evidence (RWE) in drug development helps in gaining a deep insight into how real-world data and experiences come together to shape impactful pharmaceutical solutions. Introduction to […] The post The Role of Real-World Evidence (RWE) in Drug Development: ProRelix Research Insights appeared first on ProRelix Research.

More Trending

article thumbnail

Health Canada disclosing more information on pending generic drug submissions

Pharma in Brief

On February 23, 2024, Health Canada published a Notice advising that it was making its review process for generic drug submissions more transparent. Specifically, for generic drug submissions accepted into review on or after April 1, 2024, Health Canada will start disclosing: (i) the year and month that the submission was accepted for review; and (ii) the company sponsoring the generic drug.

article thumbnail

New patent expiration for Almatica drug GRALISE

Drug Patent Watch

Annual Drug Patent Expirations for GRALISE Gralise is a drug marketed by Almatica and is included in one NDA. It is available from one supplier. There is one patent protecting… The post New patent expiration for Almatica drug GRALISE appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 59
article thumbnail

Individualizing Care for Older Adults With Diabetes Amid the Revolution in Pharmacotherapy

JAMA Internal Medicine

This JAMA Network Insights reassesses the approach to caring for older adults with diabetes in the context of newly available pharmacologic agents.

51